Zanidatamab is a Bispecific antibody targeting HER2, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Lazertinib Mesylate is a Small molecule drug targeting EGFR L858R x EGFR T790M x EGFR-Ex19del, at Approved. This 2026 report reviews clinical evidence.

Pirtobrutinib is a Small molecule drug targeting BTK C481S, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Ensitrelvir Fumaric Acid: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.

Cabozantinib (s)-Malate is a Small molecule drug targeting AXL x RET x ROS1 x TYRO3 x Tie-2 x TrkB x VEGFR1 x VEGFR2 x VEGFR3 x c-Kit x c-Met, at.

Sacituzumab govitecan-hziy: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.

Lisaftoclax is a Small molecule drug targeting Bcl-2, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Inclisiran sodium is a siRNA targeting PCSK9, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Efgartigimod Alfa is a Fc Fragment targeting FcRn, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

VK-2735 is a Synthetic peptide targeting GIPR x GLP-1R, at Phase 3. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Depemokimab is a Monoclonal antibody targeting IL-5, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Nerandomilast is a Small molecule drug targeting PDE4B, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.